Bharat Biotech’s oral cholera vaccine Hillchol demonstrates success in Phase III

Bharat Biotech's Oral Cholera Vaccine Hillchol has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.

- 

The study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a doubleblind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India, Hyderabad based Vaccine maker said in a release here on Wednesday.

In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years.

They were randomized in a 3:1 ratio to receive either Hillchol or a comparator vaccine.